Arabpour Erfan, Golmoradi Hadi, Tape Parya Mozafari Komesh, Sadeghi Amir, Abdehagh Mohammad, Moghadam Pardis Ketabi, Zali Mohammad Reza
Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Clin Endosc. 2025 Jan;58(1):10-24. doi: 10.5946/ce.2024.153. Epub 2024 Nov 5.
The administration of botulinum toxin A (BTA) into the gastric wall has emerged as a novel endoscopic bariatric procedure. Although over 20 years have elapsed since the initial human trial of intragastric BTA injection, considerable debate remains surrounding the safety, efficacy, and procedural instructions of this approach. The current literature exhibits discrepancies in the methodologies employed across studies, including differences in the dosage of BTA administered, injection site, number and depth of injections, post-procedural dietary modifications, and follow-up duration. This study reviewed the state-of-the-art use of BTA for weight loss and focused on the clinical evidence of the therapeutic applications of BTA for obesity. Studies with consistent outcome measures and methodologies are necessary to thoroughly assess the potential effects of BTA on weight management.
向胃壁注射A型肉毒杆菌毒素(BTA)已成为一种新型的内镜减肥手术。尽管自首次人体胃内注射BTA试验以来已过去20多年,但围绕该方法的安全性、有效性和操作说明仍存在相当多的争论。当前文献显示,各研究采用的方法存在差异,包括所给予的BTA剂量、注射部位、注射次数和深度、术后饮食调整以及随访时间。本研究回顾了BTA用于减肥的最新应用情况,并聚焦于BTA治疗肥胖症的临床证据。需要采用一致的结局指标和方法的研究来全面评估BTA对体重管理的潜在影响。